Tesaglitazar (GALIDA™) improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population.

被引：0

作者：

Fagerberg, B

Edwards, S

Halmos, T

Lopantynski, J

Schuster, H

Stender, S

Stoa-Birketvedt, G

Tonstad, S

Gause-Nilsson, I

机构：

[1] Sahlgrens Univ Hosp, Wallenberg Lab Cardiovasc Res, S-41345 Gothenburg, Sweden

[2] N Cardiff Med Ctr, Cardiff, S Glam, Wales

[3] Natl Koranyi Inst Pulm Dis, Budapest, Hungary

[4] Lublin Med Acad, Dept Primary Hlth Serv & Family Med, Lublin, Poland

[5] INFOGEN, Berlin, Germany

[6] Gentofte Univ Hosp, Gentofte, Denmark

[7] Univ Tromso Hosp, N-9012 Tromso, Norway

[8] Ullevaal Univ Hosp, Oslo, Norway

[9] AstraZeneca R&D, Molndal, Sweden

来源：

DIABETOLOGIA | 2003年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

175

引用

页码：A63 / A63

页数：1

共 50 条

[1] Tesaglitazar improves apolipoprotein abnormalities in an insulin resistant, non-diabetic population
Schuster, HM
Fagerberg, B
Edwards, S
Halmos, T
Lopatynski, J
Stender, S
Stoabirketvedt, G
Tonstad, S
Öhman, P
Gause-Nilsson, I
DIABETES, 2005, 54 : A238 - A238
[2] Tesaglitazar (GALIDA™) improves postprandial lipid handling and glucose tolerance in an insulin-resistant, non-diabetic population
Fagerberg, B
Edwards, S
Halmos, T
Lopatynski, J
Schuster, H
Stender, S
Birketvedt, GS
Tonstad, S
Öhman, P
Gause-Nilsson, I
DIABETES, 2005, 54 : A152 - A152
[3] Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population
B. Fagerberg
S. Edwards
T. Halmos
J. Lopatynski
H. Schuster
S. Stender
G. Stoa-Birketvedt
S. Tonstad
S Halldórsdóttir
I. Gause-Nilsson
Diabetologia, 2005, 48 : 1716 - 1725
[4] Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population
Fagerberg, B
Edwards, S
Halmos, T
Lopatynski, J
Schuster, H
Stender, S
Stoa-Birketvedt, G
Tonstad, S
Halldórsdóttir, S
Gause-Nilsson, I
DIABETOLOGIA, 2005, 48 (09) : 1716 - 1725
[5] The Number of Metabolic Abnormalities Associated with the Risk of Gallstones in a Non-diabetic Population
Tsai, Chung-Hung
Wu, Jin-Shang
Chang, Yin-Fan
Lu, Feng-Hwa
Yang, Yi-Ching
Chang, Chih-Jen
PLOS ONE, 2014, 9 (03):
[6] Tesaglitazar reduced the prevalence of metabolic syndrome and impaired fasting glucose in an insulin-resistant, non-diabetic population
Schuster, HM
Fagerberg, B
Edwards, S
Halmos, T
Lopatynski, J
Stender, S
Birketvedt, GS
Tonstad, S
Öhman, P
Gause-Nilsson, I
DIABETES, 2005, 54 : A152 - A152
[7] Metabolic signatures of insulin resistance in non-diabetic individuals
Arjmand, Babak
Fana, Saeed Ebrahimi
Ghasemi, Erfan
Kazemi, Ameneh
Ghodssi-Ghassemabadi, Robabeh
Dehghanbanadaki, Hojat
Najjar, Niloufar
Kakaii, Ardeshir
Forouzanfar, Katayoon
Nasli-Esfahani, Ensieh
Farzadfar, Farshad
Larijani, Bagher
Razi, Farideh
BMC ENDOCRINE DISORDERS, 2022, 22 (01)
[8] Metabolic signatures of insulin resistance in non-diabetic individuals
Babak Arjmand
Saeed Ebrahimi Fana
Erfan Ghasemi
Ameneh Kazemi
Robabeh Ghodssi-Ghassemabadi
Hojat Dehghanbanadaki
Niloufar Najjar
Ardeshir Kakaii
Katayoon Forouzanfar
Ensieh Nasli-Esfahani
Farshad Farzadfar
Bagher Larijani
Farideh Razi
BMC Endocrine Disorders, 22
[9] Tesaglitazar, a dual peroxisome proliferator-activated receptor α/γ agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance
Schuster, Herbert
Fagerberg, Bjorn
Edwards, Sion
Halmos, Tamas
Lopatynski, Jerzy
Stender, Steen
Birketvedt, Grethe Stoa
Tonstad, Serena
Gause-Nilsson, Ingrid
Halldorsdottir, Sigrun
Oehman, K. Peter
ATHEROSCLEROSIS, 2008, 197 (01) : 355 - 362
[10] Fluvastatin improves insulin resistance in non-diabetic dyslpidemic patients
Sonmez, A
Yilmaz, M
Kilic, M
Baykal, Y
Kocar, Y
ATHEROSCLEROSIS SUPPLEMENTS, 2004, 5 (01) : 60 - 60

← 1 2 3 4 5 →